BioCentury
ARTICLE | Finance

Private Rounds: Ice pack

November 3, 1997 8:00 AM UTC

While the public markets were in meltdown, a number of privately owned European companies were either completing or announcing financing rounds.

Biotrin Holdings was expected to announce today completion of its third round of financing, which will raise IRL7.6 million (US$11.2 million). All existing shareholders - Biotechnology Investments Ltd., New York Life Insurance, Forbairt, ICC Bank Ventures, Delta Partners, and IIU Ltd. - participated in this pre-IPO round. Other investors include Credit Suisse Asset Management, Reabourne Merlin Life Sciences Investment Trust plc, and Curran Capital. Nomura International plc acted as the financial adviser and underwriter. Biotrin, which is selling assays for organ damage, is expecting to do an IPO within the next 12 months. The London Stock Exchange seems to be the favorite although the company has not ruled out either EASDAQ or NASDAQ...